Crista Ochsenfarth

Ms. Crista Ochsenfarth

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2018 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
PDF file
Ulrich FreyUlrich Frey
Ulrich Frey
MKMarina Klaassen
Marina Klaassen
COCrista Ochsenfarth
Crista Ochsenfarth
FMFlorian Murke
Florian Murke
MTMatthias Thielmann
Matthias Thielmann
JPJürgen Peters
Jürgen Peters

3 March 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
DDDavid Díaz-Carballo
David Díaz-Carballo
SSSahitya Saka
Sahitya Saka
AAAli H. Acikelli
Ali H. Acikelli
EHEkaterina Homp
Ekaterina Homp
JEJulia Erwes
Julia Erwes
DSDirk Strumberg
Dirk Strumberg
In this work, we are reporting that “Shock and Kill”, a therapeutic approach designed to eliminate latent HIV from cell reservoirs, is extrapolatable to cancer therapy. This is based on the observation that malignant cells express a spectrum of human endogenous retroviral elements (HERVs) which can be transcriptionally boosted by HDAC inhibitors. The endoretroviral geneHERV-V2codes for an envelope protein, which resembles syncytins. It is significantly overexpressed upon exposure to HDAC inhibitors and can be effectively targeted by simultaneous application of TLR7/8 agonists, triggering intrinsic apoptosis. We demonstrated that this synergistic cytotoxic effect was accompanied by the functional disruption of the TLR7/8-NFκB, Akt/PKB, and Ras-MEK-ERK signalling pathways. CRISPR/Cas9 ablation ofTLR7andHERV-V1/V2curtailed apoptosis significantly, proving the pivotal role of these elements in driving cell death. The effectiveness of this new approach was confirmed in ovarian tumour xenograft studies, revealing a promising avenue for future cancer therapies.

15 June 2018 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
SKStefanie Klenke
Stefanie Klenke
AEAndrea Engler
Andrea Engler
DEDaniel Ecker
Daniel Ecker
COCrista Ochsenfarth
Crista Ochsenfarth
NDNina Danowski
Nina Danowski
Ulrich FreyUlrich Frey
Ulrich Frey

Verified
Journal Article
Open access
PDF file
PPPhuong N. V. Pham
Phuong N. V. Pham
LYLoubna Yahsaly
Loubna Yahsaly
COCrista Ochsenfarth
Crista Ochsenfarth
BGBernd Giebel
Bernd Giebel
RSRomina Schnitzler
Romina Schnitzler
Ulrich FreyUlrich Frey
Ulrich Frey
Remote ischemic preconditioning (RIPC) reduces ischemia-reperfusion injury in aortocoronary bypass surgery, potentially via extracellular vesicles (EVs) and their micro-RNA content. Clinical data implicate that propofol might inhibit the cardioprotective RIPC effect. This prospective, randomized study investigated the influence of different anesthetic regimes on RIPC efficacy and EV micro-RNA signatures. We also assessed the impact of propofol on cell protection after hypoxic conditioning and EV-mediated RIPC in vitro. H9c2 rat cardiomyoblasts were subjected to hypoxia, with or without propofol, and subsequent simulated ischemia-reperfusion injury. Apoptosis was measured by flow cytometry. Blood samples of 64 patients receiving anesthetic maintenance with propofol or isoflurane, along with RIPC or sham procedures, were analyzed, and EVs were enriched using a polymer-based method. Propofol administration corresponded with increased Troponin T levels (4669 ± 435.6 pg/mL), suggesting an inhibition of the cardioprotective RIPC effect. RIPC leads to a notable rise in miR-21 concentrations in the group receiving propofol anesthesia (fold change 7.22 ± 6.6). In vitro experiments showed that apoptosis reduction was compromised with propofol and only occurred in an EV-enriched preconditioning medium, not in an EV-depleted medium. Our study could clinically and experimentally confirm propofol inhibition of RIPC protection. Increased miR-21 expression could provide evidence for a possible inhibitory mechanism.

26 April 2012
Verified
Book Chapter
Closed access
PDF file
HNHolger Nückel
Holger Nückel
ECErick Castelli
Erick Castelli
Philippe MoreauPhilippe Moreau
Philippe Moreau
COCrista Ochsenfarth
Crista Ochsenfarth
PHPeter A. Horn
Peter A. Horn
VRVera Rebmann
Vera Rebmann

18 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMaike Stegen
Maike Stegen
AEAndrea Engler
Andrea Engler
COCrista Ochsenfarth
Crista Ochsenfarth
IMIris Manthey
Iris Manthey
JPJürgen Peters
Jürgen Peters
Ulrich FreyUlrich Frey
Ulrich Frey
Background: G protein-coupled receptor kinase 6 (GRK6) is part of the G protein-coupled receptor kinase family, whose members act as key regulators of seven-transmembrane receptor signalling. GRK6 seems to play a role in regulation of inflammatory processes, but mechanisms of transcriptional regulation of GRK6 expression in inflammatory cell lines have not been characterized. Protein kinase C (PKC) signalling is also involved in inflammatory regulation and an impact of PKC activation on GRK6 protein expression was described previously. Thus, the aim of this study was to 1) characterize theGRK6promoter, and 2) investigate a potential influence of PKC on GRK6 expression.Methods: Five deletion constructs of theGRK6promoter were cloned. After transient transfection into a human T cell line, promoter activity was assessed using luciferase reporter gene assays. Putative transcription factor binding sites were identified, mutated, and binding was investigated using electrophoretic mobility shift assays (EMSA). Following stimulation with a PKC activator, GRK6 expression on mRNA and protein levels was assessed by reverse transcriptase qPCR and Western blots.Results: Investigation of theGRK6promoter revealed a putative cAMP responsive element (CRE), whose mutation led to decreased promoter activity (p = 0.0006). Functionality of the CRE binding protein (CREB) binding site was verified in EMSA blots. Stimulation with a PKC activator resulted in decreasedGRK6promoter activity (p = 0.0027), mRNA (p = 0.04) and protein expression.Conclusion: We characterized the humanGRK6promoter and identified promoter activity to be influenced by a CREB binding site. PKC might be one determinant contributing to altered GRK6 expression.